A global health company is seeking one-dose administration pulse-release drug delivery platforms for vaccines and biologics. Specifically, the team is seeking platforms that produce an initial burst release, followed by a second programmed burst release that occurs 2-4 weeks following administration. The platform should have a favourable safety data package including residual and site reactions after the administration and release. The team is interested in materials and formulations, provided the platform can deliver a reproducible, tunable second pulse in this timeframe while maintaining biologic integrity and potency. 
Approaches of Interest:
<ul>
<li>The delivery platform should be compatible with whole organism proteins and peptides or RNA/ DNA. Compatibility with adjuvants is also sought. </li>
<li>The platform should be able to be used in subcutaneous, intramuscular, and in ovo formulation.</li>
<li>The stability of the formulation should maintain activity of the biologic, including minimizing aggregation and denaturation and addressing potential acidic microclimates caused by polymers. </li>
<li>The formulation components should be attainable from commercial sources. </li>
<li>Ideally, materials used for manufacturing of drug product should be regulatory approved with established toxicity profile. Solutions with novel materials are also sought. </li>
<li>The formulation should be manufactured via a scalable process and sterile/aseptic path, with acceptable excipients and reasonable cost of goods across animal health applications. </li>
<li>Formulations should be capable of thoroughly characterized, especially the quantification of biological active components. </li>
<li>If unique device for application is required, please provide details. </li>
</ul>
Out of Scope:
<ul>
<li>Formulations that include materials from animal origin. </li>
<li>Patch formulations or solutions that require large or expensive equipment to trigger the second pulse. </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities should have in vitro and in vivo data demonstrating pulse timing in the 2-4 weeks window. Encouraged to have animal data. </li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should also include IP information, if available, including a summary of patents (granted or pending), filing jurisdictions. This campaign is open to submissions from SMEs and start-up companies. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Our client is seeking drug delivery platforms for vaccines and biologics that provide an initial burst release and a programmed second pulse release 2-4 weeks after administration.

Seeking Pulse-release Drug Delivery Platforms 

Regeneron Genetics Center® (RGC) is seeking collaborators with well‑characterized human subject cohorts for specific diseases. The focus is on accessing human biospecimens appropriately consented for genetic sequencing, alongside de‑identified clinical and phenotypic data, for internal research and development purposes. In exchange, RGC will generate research‑use‑only genetic sequencing data and return all sequencing data to the collaborator to support their non‑profit research.
Approaches of Interest:
<ul>
<li>RGC is open to all disease areas, with a particular focus on oncology, immunological, neurological and psychiatric, ophthalmologic, and cardiovascular and metabolic disorders. Please refer to the submission form for further details </li>
<li>Ideal applicants may demonstrate strengths across areas such as sample size, availability of appropriate controls, depth of phenotypic data, genetic diversity, availability of serum/plasma in addition to DNA</li>
<li>Most or all of the samples should be banked (rather than prospective) </li>
<li>Data derived from individual demographic groups—for example, women, or specific local demographic or genetic backgrounds—are also of interest </li>
</ul>
Submission Information
Applicants should complete the <a href="">submission form</a> which should contain a brief, non‑confidential overview of your proposal, demonstrating how the RFP requirements are satisfied by your approach. Proposals should outline any resources required to enable a collaboration. To submit your proposal, please visit our <a href="">website</a>, register, and submit your application form under the appropriate Connect campaign. The RGC requires that Informed Consent signed by research participants is appropriate for the proposed collaboration and that the IRB approval is obtained before commencing a collaboration.
Opportunity for Collaboration
Each selected partner will receive in‑kind DNA sequencing (whole‑exome sequencing and genome‑wide genotyping) performed by RGC, with all sequencing data returned for internal research use and non‑commercial sharing. Publication of results is encouraged following a brief advance review period. 
RGC will provide tubes for sample transfer, cover shipping costs, and generate sequencing data at its expense. Collaboration‑specific operational funding may be provided under mutually agreed terms, dependent on cohort uniqueness, size, and phenotypic depth. Optional additional in‑kind molecular assays and future collaboration opportunities may be considered on a case‑by‑case basis.

Regeneron Genetics Center® is seeking collaborators that have assembled deep, well-characterized human subject cohorts for specific diseases. The focus is on accessing human biospecimens appropriately consented for genetic sequencing.

Seeking Collaborative Partners to Advance Human Genomic Discoveries in Health and Disease 

Johnson &amp; Johnson is seeking novel, differentiated technologies with the potential to deliver superior safety and efficacy in the treatment of solid tumors. The primary focus is on solid tumors, with interest in platforms with potential applications to hematologic malignancies. 
<h3>Specific Areas of Interest Include:</h3>
<ul>
<li>Indications of interest include lung, head and neck, bladder, gastrointestinal, and colorectal cancers </li>
<li>Clinical-stage or near-clinical-stage assets with first/best in class potential providing better solutions for patients </li>
<li>Earlier-stage assets of interest include novel, differentiated tumor-associated or tumor-specific targets; conditional and logic-gated approaches (e.g., AND-gating or multi-input control strategies) across modalities; and cell therapies, including CAR-T platforms and assets</li>
</ul>
<h3>Out of Scope:</h3>
<ul>
<li>Opportunities relating to vaccines, gene therapy and personalized solutions</li>
</ul>
<h3>Submission Information and Opportunity for Collaboration</h3>
Applicants should complete the <a href="">submission form</a> which should contain a brief, non‑confidential overview of your science, demonstrating how the RFP requirements are satisfied by your approach. Submissions should outline the resources required to solve the problem. To submit your application, please visit our <a href="">website</a>, register, and submit your application form under the appropriate Connect campaign. Alongside your submission form, Johnson &amp; Johnson requires the upload of a mandatory slide deck. In submitting to this campaign, you agree to Johnson &amp; Johnson’s <a href="">Terms and Conditions</a>. 
Submissions will be evaluated by a panel of reviewers on their ability to meet the following criteria:
<ul>
<li>Alignment with areas of focus </li>
<li>Potential impact for transforming health outcomes for people living with solid tumors </li>
<li>Feasibility of the idea or methodology and supporting data as a proof of concept </li>
<li>Identification of key resources and a plan to further the idea </li>
<li>Team quality and capabilities </li>
</ul>
Selected applicants may have the chance to present their science to Johnson &amp; Johnson Innovative Medicine Oncology leaders during the World Conference on Lung Cancer in Seoul, South Korea, during the week of September 12-15, 2026.

Johnson & Johnson is seeking novel, differentiated technologies with the potential to deliver superior safety and efficacy in the treatment of solid tumors.

Seeking Next-generation Advances Targeting Solid Tumors 

Bayer Crop Science is seeking innovative solutions to alter chromosomal recombination frequency to drive variation in crop plants. Solutions that may be temporal or heritable and impact general recombination frequency or site-specific recombination frequency are of high interest. 
Approaches of Interest:
<ul>
<li>Technologies that increase general recombination frequency </li>
<li>Technologies that can be switched on or off to modulate recombination rates under defined conditions </li>
<li>A broad range of solution types, including genome editing, transgenesis, native genetic variation and chemical or environmental treatments</li>
<li>Platform technologies for the efficient detection of rare recombination events are of interest but must be paired with methods that alter recombination frequency </li>
<li>Proof-of-concept demonstrated in model plant systems, with readiness for translation to crop plants </li>
</ul>
Out of Scope:
<ul>
<li>Technology innovations outside of plants without evidence of translation to plants (e.g. mammalian chromosomal recombination modification technology) </li>
<li>Platforms for efficiently detecting or screening rare recombination events that are not paired with a method to affect recombination frequency </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Basic research through to market is of interest, provided there is proof-of-concept </li>
<li>Novel and innovative approaches are of highest interest </li>
</ul>
Submission Information
Bayer Crop Science invites applications from both academic institutions and industry organizations and welcomes proposals based on both existing technologies or methods and novel approaches. Applicants should complete the <a href="">submission form</a> which should contain a brief, non‑confidential overview of your proposal, demonstrating how the RFP requirements are satisfied by your approach. Proposals should outline the resources required to solve the problem. To submit your proposal, please visit our <a href="">website</a>, register, and submit your application form under the appropriate Connect campaign 
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Bayer Crop Science is seeking innovative solutions to alter chromosomal recombination frequency to drive variation in crop plants. Solutions that impact general recombination frequency or site-specific recombination frequency are of high interest. 

Seeking Innovations for Altering Chromosomal Recombination in Crop Plants 

The Impulse by Chiesi, the Open Innovation team within the global research-oriented biopharmaceutical group, is launching a call for innovative in utero therapeutic solutions for the treatment of rare diseases. Their focus is on approaches that enable early intervention to prevent or significantly reduce disease burden before birth.
Approaches of Interest:
<ul>
<li>Indications of highest interest include inborn errors of metabolism; dermatologic, haematologic, and immunologic conditions; endocrine-metabolic diseases; and adjacent areas such as kidney disease </li>
<li>Ultra‑rare diseases (≤1 in 50,000) will be considered </li>
<li>Treatments capable of crossing the placenta are also of interest </li>
<li>Any therapeutic modalities that lead to rare disease treatment in utero would be accepted if they meet the criteria below: 
<ul>
<li>Demonstrate or plausibly support biological efficacy </li>
<li>Be suitable for prenatal administration </li>
<li>Present a clear translational pathway, including delivery, safety, and durability considerations </li>
</ul>
</li>
</ul>
Out of Scope:
<ul>
<li>Opportunities related to oncology and infectious disease </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities from basic research phase to registration are within scope </li>
<li>Opportunities should provide, at a minimum, in vitro data, a detailed outline of the proposed next research steps, and the funding required to achieve the upcoming research milestones </li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Applicants are strongly encouraged to include a slide-deck (or similar presentation) outlining their solution. The Impulse by Chiesi welcomes submissions from all applicants, including early-stage researchers, using this <a href="">submission form</a> to describe their research and proposed next steps. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
The Impulse by Chiesi is open to a range of collaboration models, including support for small proof-of-concept or pilot studies to validate solutions that align with its needs. Details regarding intellectual property and licensing will be discussed on a case‑by‑case basis. By submitting to this campaign, you confirm that your submission contains only non-confidential information.

The Impulse by Chiesi is seeking innovative in-utero therapeutic solutions for the treatment of rare diseases. Their focus is on approaches that enable early intervention to prevent or significantly reduce disease burden before birth. 

Seeking in utero Treatments for Rare Diseases 

Grünenthal, a global leader in pain management and related diseases, is seeking therapeutic molecules for oral administration that address both the inflammatory and itch components of inflammatory diseases, such as atopic dermatitis. The team is particularly interested in innovative approaches that address the neuroimmune drivers of chronic itch, via targeting itch-mediating pruriceptors or approaches that modulate the immune-pruriceptor interaction. 
Approaches of Interest:
<ul>
<li>Diseases of particular interest include dermatological diseases, including but not limited to atopic dermatitis, hidradenitis suppurativa, urticaria and prurigo nodularis</li>
<li>Therapeutic molecules developed for non-dermatological inflammatory diseases targeting relevant pathways for the treatment of itch</li>
<li>Focus on small molecule assets for oral/ systemic administration</li>
</ul>
Out of Scope:
<ul>
<li>Therapeutics for topical administration</li>
<li>Drug discovery platforms </li>
<li>Clinical stage opportunities </li>
</ul>
Developmental Stages of Interest: 
<ul>
<li>Opportunities that have tangible chemical matter to late preclinical are in scope </li>
<li>Opportunities at lead optimization stage are highest priority </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should contain information on the therapeutics molecule’s mode of action or scientific rationale, any completed experimental validation, and how it is differentiated from known approaches. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
Opportunity for Collaboration
Grünenthal is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Grünenthal is seeking novel small molecule therapeutics for oral administration that address the neuroimmune drivers of chronic itch.

Engage with world leading R&D teams

Active campaigns

ico

Seeking Pulse-release Drug Delivery Platforms

Previous campaigns

rfp

Seeking Collaborative Partners to Advance Human Genomic Discoveries in Health and Disease

rfp

Seeking Next-generation Advances Targeting Solid Tumors

rfp

Seeking Innovations for Altering Chromosomal Recombination in Crop Plants

ico

Seeking in utero Treatments for Rare Diseases

ico

Seeking Drug Discovery Projects Targeting Itch in Inflammatory Conditions

Trusted by